Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

This study suggests that natural molecules like curcumin, EGCG, barringtozenol, and finasteride may be effective inhibitors for VEGFR, potentially offering a cancer chemoprevention alternative to pazopanib.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This report describes a case where a 44-year-old male treated with vorasidenib for diffuse low-grade gliomas developed unexpected hair growth, including in areas of severe hair loss, after one month, highlighting a previously undocumented side effect.

In this study, FOL-026, a peptide based on osteopontin, was shown to promote angiogenesis and stimulate vascular cell proliferation and migration through neuropilin-1, similar to VEGF, suggesting potential therapeutic applications in vascular repair and angiogenesis-related conditions.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This review discusses the potential of advanced therapy medicinal products for treating vitiligo, highlighting promising results but noting affordability remains a challenge; no new clinical results were reported.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.

In this Stanford study, verteporfin was used to promote scarless skin regeneration by inhibiting YAP activity in a 27-year-old female, resulting in increased hair density at the treated site compared to the untreated control.

This review highlights that vitexin, a natural flavonoid derived from plants like mung bean, modulates critical cellular processes involved in cancer progression, suggesting its potential as a multi-target anticancer treatment in preclinical studies.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This study found that topical Vorinostat induced significant hair regrowth in mice with alopecia areata, suggesting it as a potential repurposable treatment for the condition.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This study identified neuropilin-1 as the receptor for FOL-026 and showed that it stimulates angiogenesis and cell growth, suggesting potential for vascular repair and enhanced angiogenesis therapies.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.